Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to stop nausea caused by popular Weight-Loss drugs

NCT ID NCT07446439

Symptom relief Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tests whether tradipitant can reduce nausea and vomiting caused by GLP-1 weight-loss drugs. About 280 healthy overweight or obese adults will receive either tradipitant or a placebo. The goal is to see if tradipitant helps people tolerate these medications better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tradipitant (oral capsule)
What this could lead to
If it works, this could offer a way to manage nausea and vomiting for people taking GLP-1 weight-loss medications, making them easier to tolerate.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not reduce symptoms better than a placebo, and side effects are possible.
Why investors are watching

Vanda Pharmaceuticals is running a Phase 3 trial testing whether its drug tradipitant can ease nausea and vomiting caused by GLP-1 weight-loss drugs. For a small company, this readout matters because a positive result could open a new use for an existing drug, giving Vanda a second product line beyond its current focus.

If it works: If the trial succeeds, Vanda could gain approval to market tradipitant as a treatment for a common side effect of popular weight-loss medications, potentially expanding its revenue base. That outcome would make the company less dependent on its existing products.

If it fails: The trial could fail to show that tradipitant beats a placebo, which would end this potential new use and leave Vanda without a clear growth driver. Clinical trials often fail, so investors should treat this readout as uncertain.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body Mass Index ≥ 25 and \< 40 kg/m\^2 * No serious medical problems or chronic diseases, specifically no type I or type II diabetes Exclusion Criteria: * Another disorder that contributes to gastrointestinal symptoms * History of intolerance and/or hypersensitivity to NK-1 receptor antagonists * History of intolerance and/or hypersensitivity to GLP-1 receptor agonists * Exposure to any investigational medication within the past 60 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nausea and vomiting are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Nausea Obesity obesity disorder Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nausea and vomiting Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    10 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Vanda Investigational Site

    RECRUITING

    Los Angeles, California, 90025, United States

  • Vanda Investigational Site

    RECRUITING

    San Diego, California, 92108, United States

  • Vanda Investigational Site

    NOT_YET_RECRUITING

    San Jose, California, 95124, United States

  • Vanda Investigational Site

    RECRUITING

    Tampa, Florida, 33613, United States

  • Vanda Investigational Site

    NOT_YET_RECRUITING

    Hamilton, New Jersey, 08690, United States

  • Vanda Investigational Site

    NOT_YET_RECRUITING

    New York, New York, 10016, United States

  • Vanda Investigational Site

    NOT_YET_RECRUITING

    Syosset, New York, 11791, United States

  • Vanda Investigational Site

    NOT_YET_RECRUITING

    Plano, Texas, 75024, United States

  • Vanda Investigational Site

    NOT_YET_RECRUITING

    San Antonio, Texas, 78215, United States

  • Vanda Investigational Site

    NOT_YET_RECRUITING

    Burke, Virginia, 22015, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.